Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003; 98:1802–10

Hetty Carraway,Antonio C Wolff

doi:10.1016/j.ctrv.2004.01.008

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003; 98:1802–10

Hetty Carraway, Antonio C Wolff

https://doi.org/10.1016/j.ctrv.2004.01.008

Copy DOI

Journal: Evidence-based Oncology	Publication Date: Apr 9, 2004
Citations: 2

#Arimidex, Tamoxifen Alone Or In Combination #Adjuvant Treatment Of Postmenopausal Women + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003; 98:1802–10

Full Text